Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11,922 GBX | -0.88% | -3.30% | +12.75% |
09:56am | AstraZeneca drug lowers cholesterol in phase 1 trial | AN |
09:46am | Cellectis: operations financed until 2026 | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.75% | 238B | |
+38.59% | 727B | |
+29.91% | 592B | |
-7.89% | 347B | |
+15.66% | 319B | |
+0.24% | 274B | |
+7.01% | 204B | |
-5.77% | 203B | |
-1.70% | 160B | |
-2.94% | 120B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca's Asthma Drug Cuts Risk Of Severe Exacerbations In Late-stage Study